C4 Therapeutics (CCCC) Operating Income: 2019-2025
Historic Operating Income for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$34.4 million.
- C4 Therapeutics' Operating Income fell 21.84% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 8.76%. This contributed to the annual value of -$119.6 million for FY2024, which is 13.97% up from last year.
- According to the latest figures from Q3 2025, C4 Therapeutics' Operating Income is -$34.4 million, which was down 20.74% from -$28.5 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Operating Income ranged from a high of -$15.3 million in Q4 2021 and a low of -$38.3 million during Q4 2022.
- For the 3-year period, C4 Therapeutics' Operating Income averaged around -$31.9 million, with its median value being -$32.2 million (2024).
- Per our database at Business Quant, C4 Therapeutics' Operating Income plummeted by 151.02% in 2022 and then spiked by 42.92% in 2024.
- Quarterly analysis of 5 years shows C4 Therapeutics' Operating Income stood at -$15.3 million in 2021, then tumbled by 151.02% to -$38.3 million in 2022, then rose by 2.26% to -$37.4 million in 2023, then dropped by 0.75% to -$37.7 million in 2024, then decreased by 21.84% to -$34.4 million in 2025.
- Its Operating Income was -$34.4 million in Q3 2025, compared to -$28.5 million in Q2 2025 and -$29.2 million in Q1 2025.